ORDINAL – Page 2

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Novartis Secures First-Line Approval for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia Patients

6 months ago talkbio0Tagged Approved, Diagnosis, First-Line Approval, Myeloid Leukemia, Chronic, Novartis, Scemblix, United States Food and Drug Administration

Scemblix, Novartis, first-line approval, chronic myeloid leukemia, CML, newly diagnosed, FDA approval

Fierce Pharma AsiaAstellas’ first-in-class FDA nod; Otsuka’s IgAN win; Samsung Bio’s $1.2B contract

6 months ago talkbio0Tagged Contract agreement, first, IGA Glomerulonephritis, Samsung, Sibeprenlimab, United States Food and Drug Administration

United States Food and Drug Administration, IGA Glomerulonephritis, Sibeprenlimab, Contract agreement, Samsung, first

Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer

6 months ago talkbio0Tagged atezolizumab, ES-SCLC, first-line, Jazz, lurbinectedin, Phase 3 IMforte trial, Small cell carcinoma of lung, Zepzelca

Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial